Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update.
Publication
, Journal Article
Hicks, JK; Sangkuhl, K; Swen, JJ; Ellingrod, VL; Müller, DJ; Shimoda, K; Bishop, JR; Kharasch, ED; Skaar, TC; Gaedigk, A; Dunnenberger, HM ...
Published in: Clin Pharmacol Ther
July 2017
CYP2D6 and CYP2C19 polymorphisms affect the exposure, efficacy and safety of tricyclic antidepressants (TCAs), with some drugs being affected by CYP2D6 only (e.g., nortriptyline and desipramine) and others by both polymorphic enzymes (e.g., amitriptyline, clomipramine, doxepin, imipramine, and trimipramine). Evidence is presented for CYP2D6 and CYP2C19 genotype-directed dosing of TCAs. This document is an update to the 2012 Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants.
Duke Scholars
Altmetric Attention Stats
Dimensions Citation Stats
Published In
Clin Pharmacol Ther
DOI
EISSN
1532-6535
Publication Date
July 2017
Volume
102
Issue
1
Start / End Page
37 / 44
Location
United States
Related Subject Headings
- Treatment Outcome
- Polymorphism, Genetic
- Pharmacology & Pharmacy
- Pharmacogenomic Variants
- Medication Therapy Management
- Humans
- Genotyping Techniques
- Dose-Response Relationship, Drug
- Cytochrome P-450 CYP2D6
- Cytochrome P-450 CYP2C19
Citation
APA
Chicago
ICMJE
MLA
NLM
Hicks, J. K., Sangkuhl, K., Swen, J. J., Ellingrod, V. L., Müller, D. J., Shimoda, K., … Stingl, J. C. (2017). Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther, 102(1), 37–44. https://doi.org/10.1002/cpt.597
Hicks, J. K., K. Sangkuhl, J. J. Swen, V. L. Ellingrod, D. J. Müller, K. Shimoda, J. R. Bishop, et al. “Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update.” Clin Pharmacol Ther 102, no. 1 (July 2017): 37–44. https://doi.org/10.1002/cpt.597.
Hicks JK, Sangkuhl K, Swen JJ, Ellingrod VL, Müller DJ, Shimoda K, et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther. 2017 Jul;102(1):37–44.
Hicks, J. K., et al. “Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update.” Clin Pharmacol Ther, vol. 102, no. 1, July 2017, pp. 37–44. Pubmed, doi:10.1002/cpt.597.
Hicks JK, Sangkuhl K, Swen JJ, Ellingrod VL, Müller DJ, Shimoda K, Bishop JR, Kharasch ED, Skaar TC, Gaedigk A, Dunnenberger HM, Klein TE, Caudle KE, Stingl JC. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther. 2017 Jul;102(1):37–44.
Published In
Clin Pharmacol Ther
DOI
EISSN
1532-6535
Publication Date
July 2017
Volume
102
Issue
1
Start / End Page
37 / 44
Location
United States
Related Subject Headings
- Treatment Outcome
- Polymorphism, Genetic
- Pharmacology & Pharmacy
- Pharmacogenomic Variants
- Medication Therapy Management
- Humans
- Genotyping Techniques
- Dose-Response Relationship, Drug
- Cytochrome P-450 CYP2D6
- Cytochrome P-450 CYP2C19